KSPHF:OTCMKTS
Kissei Pharmaceutical Co Ltd
24,50Â US$
0,00%
(0,00) 1K
1-okt, 10:21:43 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoKSPHF tikeri uchun statistika yaratilmoqda...
Bozor kapitali
172,67Â mlrd
Oʻrtacha hajm
20,00
Hajmi
0,00
52 haftalik eng yuqori
31,90Â US$
52 haftalik eng past
24,50Â US$
Beta
13,94
Muomaladagi aksiyalar
46,54Â mln
Xodimlar soni
2Â ming
Bozor kapitali
172,67Â mlrd
Oʻrtacha hajm
20,00
Hajmi
0,00
52 haftalik eng yuqori
31,90Â US$
52 haftalik eng past
24,50Â US$
Beta
13,94
Muomaladagi aksiyalar
46,54Â mln
Xodimlar soni
2Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
PR Newswire
·
15 daqiqa oldin
Fluence Energy (NASDAQ: FLNC) Faces Securities Class Action Amid Inability to Ramp Houston Facility - HBSS
Seeking Alpha
·
16 daqiqa oldin
S&P 500 surpasses 1,000 trading days without a new 52-week low
IndexBox
·
15 daqiqa oldin
S&P 500 Record High Masks US Household Financial Strain
Yahoo Finance
·
2 soat oldin
A handful of tech stocks are masking an ugly S&P 500 problem
Profil
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Kissei Pharmaceutical Co Ltd haqida
CEOMutsuo Kanzawa
Xodimlar soni1,79Â ming
Asos solingan9-avg, 1946
Bosh ofislarMatsumoto, Nagano, Yaponiya
Sektor-
Veb-saytkissei.co.jp